This document summarizes several new drugs approved in 2018, including their mechanisms of action and uses. Some key drugs are Lutathera for gastroenteropancreatic neuroendocrine tumors, Bictegravir and Apalutamide for HIV and prostate cancer, Tezacaftor/Ivacaftor for cystic fibrosis, and Ibalizumab for multidrug resistant HIV. Other notable drugs include Fostamatinib for immune thrombocytopenic purpura, Erenumab for migraine prevention, and Lokelma for hyperkalemia. Overall, this list covers new drugs across several therapeutic areas that were approved in 2018.
This document summarizes several new drugs approved in 2018, including their mechanisms of action and uses. Some key drugs are Lutathera for gastroenteropancreatic neuroendocrine tumors, Bictegravir and Apalutamide for HIV and prostate cancer, Tezacaftor/Ivacaftor for cystic fibrosis, and Ibalizumab for multidrug resistant HIV. Other notable drugs include Fostamatinib for immune thrombocytopenic purpura, Erenumab for migraine prevention, and Lokelma for hyperkalemia. Overall, this list covers new drugs across several therapeutic areas that were approved in 2018.
This document summarizes several new drugs approved in 2018, including their mechanisms of action and uses. Some key drugs are Lutathera for gastroenteropancreatic neuroendocrine tumors, Bictegravir and Apalutamide for HIV and prostate cancer, Tezacaftor/Ivacaftor for cystic fibrosis, and Ibalizumab for multidrug resistant HIV. Other notable drugs include Fostamatinib for immune thrombocytopenic purpura, Erenumab for migraine prevention, and Lokelma for hyperkalemia. Overall, this list covers new drugs across several therapeutic areas that were approved in 2018.
This document summarizes several new drugs approved in 2018, including their mechanisms of action and uses. Some key drugs are Lutathera for gastroenteropancreatic neuroendocrine tumors, Bictegravir and Apalutamide for HIV and prostate cancer, Tezacaftor/Ivacaftor for cystic fibrosis, and Ibalizumab for multidrug resistant HIV. Other notable drugs include Fostamatinib for immune thrombocytopenic purpura, Erenumab for migraine prevention, and Lokelma for hyperkalemia. Overall, this list covers new drugs across several therapeutic areas that were approved in 2018.
New Drug Mechanism of Action Use Lutathera Radiolabeled somatostatin Somatostatin receptor analog positive gastroenteropancreatic neuroendocrine tumors
Bictegravir Integrase inhibitor HIV
Apalutamide Androgen receptor antagonist Prostate cancer
Tezacaftor + Tezacaftor is a corrector and Cystic fibrosis in patients aged
Ivacaftor ivacaftor is a potentiator of 12 years and older who are cystic fibrosis transmembrane homozygous for the F508del regulator mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence
Ibalizumab Anti CD-4 receptor monoclonal Multidrug resistant HIV
antibody
Tildrakizumab Anti IL-23 monoclonal Ab Plaque psoriasis
Burosumab Anti Fibroblast growth factor 23 X linked hypophosphatemia
(KRN23) blocking antibody
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2018 Dr. Ranjan Kumar Patel Fostamatinib Spleen tyrosine kinase inhibitor Immune thrombocytopenic purpura
decreases cyclic AMP which polycystic kidney disease results in decreased water secretion and proliferation of cells, resulting in decreased growth of cysts
Erenumab Anti CGRP-receptor monoclonal Prophylaxis of migraine by
antibody subcutaneous route 70/140 mg once monthly
Avatrombopag oral thrombopoietin receptor Thrombocytopenia in patients
Lusutrombopag agonist with chronic liver disease, prior to any procedure
zirconium potassium-removing agent cyclosilicate preferentially captures potassium in exchange for hydrogen and sodium and increases fecal potassium excretion
Pegvaliase Phenylalanine-metabolizing Phenylketonuria who have
enzyme uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2018 Dr. Ranjan Kumar Patel
Lofexidine Central alpha-2 agonist To decrease withdrawal
symptoms in opioid dependence
Andexanet alfa Recombinant protein that is a To reverse anticoagulant
modified form of factor Xa effect of factor Xa inhibitors
Baricitinib Janus Kinase 1 and 2 inhibitor Rheumatoid arthritis not
responding to TNF alpha inhibitors
Moxidectin Stimulates glutamate sensitive O. volvulus
chloride channels, which leads to flaccid paralysis in helminths
Cannabidiol Unknown LGS or Dravet syndrome in
children more than 2 years of age
Plazomicin Aminoglycoside Complicated UTI including
pyelonephritis caused by gram negative organisms
Binimetinib MEK 1/2 inhibitor Unresectable or metastatic
melanoma which is positive for BRAF V600E or V600K mutation
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2018 Dr. Ranjan Kumar Patel Encorafenib BRAF inhibitor Used along with binimetinib for condition mentioned above
Tecovirimat Inhibits orthopoxvirus VP37 Smallpox
envelope wrapping protein
Ivosidenib Inhibitor of mutant Isocitrate Relapsed or refractory AML
Dehydrogenase 1 (IDH1) positive for Isocitrate Dehydrogenase 1 (IDH1) mutation
Tafenoquine Hypnozoite cidal drug Radical cure of malaria caused
Mogamulizumab Anti CCR4 receptor antibody Relapsed or refractory mycosis
fungoides or Sezary syndrome
Patisiran It is double stranded SiRNA Hereditary transthyretin
which degrades mutant and mediated amyloidosis wild type transthyretin (TTR) associated polyneuropathy mRNA and decreases deposition of transthyretin in tissues
that binds to active site of alpha galactosidase A and facilitates
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2018 Dr. Ranjan Kumar Patel its transfer from endoplasmic reticulum to lysosomes
Stiripentol Acts via inhibitory As an add on to clobazam for
neurotransmitter GABA treatment of LGS or Dravet syndrome
Cenegermin Recombinant human nerve Neurotrophic keratitis
(bkbj) growth factor
Lanadelumab Anti kallikrein monoclonal Prophylaxis of hereditary
antibody angioedema
Eravacycline Tetracycline Complicated abdominal
infections
Doravirine Non Nucleoside Reverse HIV
Transcriptase Inhibitor (NNRTI) Moxetumomab- Immunotoxin made up of anti Relapsed or refractory hairy Pasudotox CD-22 monoclonal antibody and cell leukemia with prior 2 pseudomonas exotoxin, PE38 systemic therapy failure including purine analogs Fremanuzumab Anti CGRP ligand monoclonal Prophylaxis of migraine Galcenezumab antibodies
Duvelisib Dual inhibitor of Relapsed or refractory CLL and
phosphatidylinositol-3 kinases SLL (PI3K) delta and gamma Cemiplimab Anti PD-1 antibody Metastatic or advanced cutaneous squamous cell
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2018 Dr. Ranjan Kumar Patel carcinoma, that can not be treated by surgery or radiation Sarecycline Tetracycline antibiotic Inflammatory non nodular acne in age group > 9 years Omadacycline Tetracycline antibiotic Community acquired pneumonia and acute bacterial skin infection Dacomitinib EGFR tyrosine kinase inhibitor Non small cell cancer of lungs
Elapegademase Recombinant adenosine Adenosine deaminase severe
deaminase enzyme combined immune deficiency (ADA-SCID) Baloxavir Inhibits viral replication by Acute uncomplicated marboxil inhibiting endonuclease activity influenza of polymerase acidic protein (present in viral RNA polymerase complex) required for viral gene transcription Rifamycin RNA polymerase inhibitor Traveler’s diarrhoea caused by E. coli Inotersen Antisense oligonueotide that Polyneuropathy of hereditary degrades wild and mutant type transthyretin mediated TTR mRNA and decreases TTR amyloidosis protein deposits in tissues Emapalumab Anti-interferon gamma Primary hemophagocytic monoclonal antibody lymphohistiocytosis (HLH) Revefenacin Long acting anticholinergic (M3 COPD antagonist)
75 Hours of Online Pharmacology Videos at www.pharmle.com
New Drugs 2018 Dr. Ranjan Kumar Patel Sufentanil Opioid agonist Acute pain not responding to other drugs Talazoparib Poly ADP ribose polymerase BRCA mutated HER2 negative (PARP) inhibitor breast cancer Lorlatinib ALK/ROS1 tyrosine kinase Non small cell lung cancer inhibitor resistant to other drugs in this class like alectinib or Ceritinib Glasdegib Hedgehog pathway inhibitor AML along with cytarabine in patients > 75 years or in patients with comorbidities that are contraindication for intensive induction chemotherapy
75 Hours of Online Pharmacology Videos at www.pharmle.com